Person
| Role | Organisation | Sources |
|---|---|---|
| No role recorded yet. David Mack has been mentioned, but not yet attached to an organisation. Know their role? | ||
Stories naming David Mack. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
DigitalX's outlook on real-world asset tokenisation: market growth since 2022, institutional pilots by major banks and asset managers, regulatory frameworks, and its DxART Fund's expansion plans for 2024.
Biotech Proacta's release: its Phase I cancer-drug trial is underway, and Alta Partners' new funding tops the Series A up to $12M alongside lead backer GBS Ventures; Alta's David Mack joins the board.